Fate Therapeutics FATE Stock
Fate Therapeutics Price Chart
Fate Therapeutics FATE Financial and Trading Overview
Fate Therapeutics stock price | 1.25 USD |
Previous Close | 5.43 USD |
Open | 5.41 USD |
Bid | 0 USD x 800 |
Ask | 0 USD x 2200 |
Day's Range | 5.36 - 5.96 USD |
52 Week Range | 4.02 - 37.13 USD |
Volume | 2.55M USD |
Avg. Volume | 2.56M USD |
Market Cap | 571.61M USD |
Beta (5Y Monthly) | 1.48838 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.49 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 8.16 USD |
FATE Valuation Measures
Enterprise Value | 232.95M USD |
Trailing P/E | N/A |
Forward P/E | -2.905 |
PEG Ratio (5 yr expected) | 0.08 |
Price/Sales (ttm) | 4.1764493 |
Price/Book (mrq) | 1.1947358 |
Enterprise Value/Revenue | 1.702 |
Enterprise Value/EBITDA | -0.942 |
Trading Information
Fate Therapeutics Stock Price History
Beta (5Y Monthly) | 1.48838 |
52-Week Change | -72.38% |
S&P500 52-Week Change | 20.43% |
52 Week High | 37.13 USD |
52 Week Low | 4.02 USD |
50-Day Moving Average | 5.58 USD |
200-Day Moving Average | 12.12 USD |
FATE Share Statistics
Avg. Volume (3 month) | 2.56M USD |
Avg. Daily Volume (10-Days) | 2.34M USD |
Shares Outstanding | 98.38M |
Float | 83.7M |
Short Ratio | 12.67 |
% Held by Insiders | 1.50% |
% Held by Institutions | 106.35% |
Shares Short | 29.12M |
Short % of Float | 37.96% |
Short % of Shares Outstanding | 29.58% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -171.63% |
Operating Margin (ttm) | -191.80% |
Gross Margin | -128.55% |
EBITDA Margin | -180.70% |
Management Effectiveness
Return on Assets (ttm) | -22.042% |
Return on Equity (ttm) | -42.29% |
Income Statement
Revenue (ttm) | 136.87M USD |
Revenue Per Share (ttm) | 1.41 USD |
Quarterly Revenue Growth (yoy) | 220.29% |
Gross Profit (ttm) | -224154000 USD |
EBITDA | -247323008 USD |
Net Income Avi to Common (ttm) | -234912000 USD |
Diluted EPS (ttm) | -2.43 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 408.9M USD |
Total Cash Per Share (mrq) | 4.16 USD |
Total Debt (mrq) | 107.62M USD |
Total Debt/Equity (mrq) | 22.54 USD |
Current Ratio (mrq) | 9.001 |
Book Value Per Share (mrq) | 4.863 |
Cash Flow Statement
Operating Cash Flow (ttm) | -212455008 USD |
Levered Free Cash Flow (ttm) | -131318376 USD |
Profile of Fate Therapeutics
Country | United States |
State | CA |
City | San Diego |
Address | 12278 Scripps Summit Drive |
ZIP | 92131 |
Phone | 858 875 1800 |
Website | https://www.fatetherapeutics.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 551 |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Q&A For Fate Therapeutics Stock
What is a current FATE stock price?
Fate Therapeutics FATE stock price today per share is 1.25 USD.
How to purchase Fate Therapeutics stock?
You can buy FATE shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Fate Therapeutics?
The stock symbol or ticker of Fate Therapeutics is FATE.
Which industry does the Fate Therapeutics company belong to?
The Fate Therapeutics industry is Biotechnology.
How many shares does Fate Therapeutics have in circulation?
The max supply of Fate Therapeutics shares is 114.63M.
What is Fate Therapeutics Price to Earnings Ratio (PE Ratio)?
Fate Therapeutics PE Ratio is now.
What was Fate Therapeutics earnings per share over the trailing 12 months (TTM)?
Fate Therapeutics EPS is -1.49 USD over the trailing 12 months.
Which sector does the Fate Therapeutics company belong to?
The Fate Therapeutics sector is Healthcare.
Fate Therapeutics FATE included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 19142.72 USD — |
-0.38
|
8.16B USD — | 19015.63 USD — | 19186.69 USD — | — - | 8.16B USD — |
NASDAQ Composite Total Return XCMP | 23450.01 USD — |
-0.38
|
— — | 23294.32 USD — | 23503.87 USD — | — - | — — |
NASDAQ Global Market Composite NQGM | 1999.47 USD — |
+0.64
|
— — | 1978.54 USD — | 2004.74 USD — | — - | — — |
NASDAQ Biotechnology NBI | 4177.94 USD — |
+1.55
|
— — | 4103.9 USD — | 4188.28 USD — | — - | — — |
Nasdaq Health Care IXHC | 955.99 USD — |
+0.93
|
— — | 944.04 USD — | 957.7 USD — | — - | — — |
Nasdaq US 700 Small Cap Index NQUS700SC | 2227.13 USD — |
+0.03
|
— — | 2216.57 USD — | 2233.85 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}